NAS:ENLV (Israel)  
Enlivex Therapeutics Ltd logo

Enlivex Therapeutics Ltd

$ 4.50 -0.14 (-3.02%) 10:08 PM EST
P/E:
At Loss
P/B:
1.21
Market Cap:
$ 82.81M
Enterprise V:
$ 23.54M
Volume:
38.15K
Avg Vol (2M):
17.91K
Also Trade In:
Volume:
38.15K
Market Cap $:
82.81M
PE Ratio:
At Loss
Avg Vol (2-Month):
17.91K
Enterprise Value $:
23.54M
PB Ratio:
1.21
GF Score:
Year:
Not Enough Data to Display
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Not Enough Data to Display
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Name Current Vs Industry Vs History
Cash-To-Debt 99.34
Equity-to-Asset 0.89
Debt-to-Equity 0.01
Debt-to-EBITDA -0.03
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 28.77
9-Day RSI 44.35
14-Day RSI 48.95
6-1 Month Momentum % -8.58
12-1 Month Momentum % -40.32

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 15.44
Quick Ratio 15.44
Cash Ratio 14.83

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -251.9
Name Current Vs Industry Vs History
ROE % -32.11
ROA % -28.93
ROIC % -256.36
ROC (Joel Greenblatt) % -308.54
ROCE % -27.82

Financials (Next Earnings Date:2022-12-02 Est.)

ENLV's 30-Y Financials

Guru Trades

See Details
To
Not Enough Data to Display

Insider Trades

See Details
To
Not Enough Data to Display

Gurus Latest Trades with NAS:ENLV

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
Not Enough Data to Display

Performance

Dividend
Log
To
Not Enough Data to Display

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Not Enough Data to Display

Valuation Box

Year:
Not Enough Data to Display

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.45
Beta 0.38
Volatility % 40.53
14-Day RSI 48.95
14-Day ATR ($) 0.215526
20-Day SMA ($) 4.516695
12-1 Month Momentum % -40.32
52-Week Range ($) 3.65 - 8.64
Shares Outstanding (Mil) 18.4

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Enlivex Therapeutics Ltd Filings

Document Form Filing Date
No Filing Data

Enlivex Therapeutics Ltd Analysis

Share your research

Headlines

See More
No news.